Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Adicet Therapeutics Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This action is assigned to 1 distinct examiner, SKELDING, ZACHARY S, who is the busiest examiner with 1 pending office action. The prosecution is concentrated in 1 distinct art unit, indicating a specialized technical focus for the active matter.
The presence of 1 distinct examiner and 1 distinct art unit shows that the portfolio's current USPTO activity is very limited in scope. For a practitioner, this means that the 1 pending office action is the only current priority in the prosecution pipeline. SKELDING, ZACHARY S is the only examiner the portfolio is currently interacting with, which allows for a focused communication strategy. The 1 distinct art unit suggests that the pending application is situated in a specific niche of Biotechnology & Pharmaceuticals.
Because there is only 1 pending office action, the portfolio's immediate growth is tied to this single examination process. This concentration simplifies the management of the portfolio but also means that any delays from the 1 distinct examiner will impact the entire active portfolio. The busiest examiner, SKELDING, ZACHARY S, holds the only 1 pending office action currently active. Practitioners should focus on the specific examination history of SKELDING, ZACHARY S to optimize the response to the 1 pending office action. This centralized approach requires high precision in the single active matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17298903 | METHODS FOR SELECTIVE IN VIVO EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | SKELDING, ZACHARY S | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17298903 | METHODS FOR SELECTIVE IN VIVO EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | 2d overdue | Pending | Jun 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial